Aplenzin carries a cash price of roughly $2,400 for a 30-day supply of the lowest strength, making it one of the most expensive antidepressants on the market. Generic bupropion, which treats the same conditions, typically costs under $30 for a month’s supply. That staggering gap comes down to a few reinforcing factors: a slightly different chemical formulation that keeps it in its own product category, limited generic competition for that specific formulation, and the pricing leverage that brand-name drugs maintain when insurers rarely push back.
A Different Salt, Same Active Ingredient
Aplenzin uses bupropion hydrobromide, while generic bupropion and Wellbutrin use bupropion hydrochloride. The active molecule, bupropion, is identical. The difference is the salt attached to it: bromide in Aplenzin, chloride in the generics. This distinction matters because it allowed the manufacturer to patent Aplenzin as a separate drug rather than compete directly with the flood of cheap generic bupropion hydrochloride that hit the market after Wellbutrin’s patents expired.
The FDA approved Aplenzin based on pharmacokinetic bioequivalence to bupropion hydrochloride, meaning the two deliver similar blood levels of the drug. No head-to-head clinical trials have ever compared them for effectiveness. Some researchers at the Neuroscience Education Institute have theorized that bromide could offer advantages, such as better penetration into the brain and a calming effect on certain brain receptors that might reduce anxiety and insomnia. But these ideas come from basic chemistry and small, unblinded retrospective analyses, not from the kind of rigorous trials that would prove a real clinical edge. In practice, most prescribers and pharmacists treat the two as interchangeable in terms of results.
Limited Generic Competition
Even though Aplenzin’s key patent expired and generic bupropion hydrobromide versions received FDA approval as early as February 2020, the generic market for this specific salt form remains small. Generic manufacturers have little incentive to aggressively produce and market bupropion hydrobromide when bupropion hydrochloride already dominates the market at rock-bottom prices. Fewer generic competitors means less downward pressure on the price of the hydrobromide version, so the brand product can hold its high list price longer than you might expect.
The final qualifying patent on Aplenzin doesn’t expire until June 2026, which may still provide some legal footing for the manufacturer to manage competition. Even where generics exist on paper, availability at your local pharmacy can be inconsistent, effectively funneling patients back to the brand.
Insurance Barriers and Formulary Status
Most insurance plans treat Aplenzin as a non-preferred or non-formulary drug. The VA health system, for example, classifies it as non-formulary and requires a special approval request before it can be dispensed, placing it on the highest copay tier. Private insurers follow a similar pattern. Because generic bupropion hydrochloride is so cheap and widely available, insurers almost always require “step therapy,” meaning you have to try (and document a poor response to) the generic version before they’ll consider covering Aplenzin.
This creates an odd dynamic. The manufacturer can keep the list price high because most patients who do get Aplenzin are funneled through a savings program rather than paying cash. Bausch Health offers a copay card that brings the cost to as little as $0 for commercially insured patients. But the card has a maximum annual benefit (the exact cap isn’t publicly disclosed), and it excludes anyone on Medicare, Medicaid, TRICARE, or any other government insurance. If you fall outside those eligibility windows, you’re looking at the full price or close to it.
How Brand Drug Pricing Works Here
Aplenzin’s price isn’t really set by what it costs to manufacture. The tablet itself is inexpensive to produce. The price reflects a strategy common in the pharmaceutical industry: create a product that occupies its own narrow category (in this case, bupropion hydrobromide rather than hydrochloride), protect it with patents, and set a high list price knowing that most patients will be shielded by insurance or copay assistance. The manufacturer collects high reimbursements from insurers on each prescription filled, and the list price serves as the starting point for those negotiations.
For the small number of patients paying out of pocket, the price is effectively a penalty for not having commercial insurance or for falling outside the savings program. This is the same mechanism that drives high prices for many brand-name drugs that have near-identical generic alternatives.
Practical Options to Lower Your Cost
If you’re currently taking Aplenzin and struggling with the price, the most straightforward option is asking your prescriber about switching to generic bupropion hydrochloride extended-release. The dose conversion is simple: 174 mg of Aplenzin equals 150 mg of bupropion hydrochloride, 348 mg equals 300 mg, and 522 mg equals 450 mg. For the vast majority of patients, the switch produces no noticeable difference in how the medication works.
If your prescriber has a specific reason for keeping you on the hydrobromide salt, check whether a generic bupropion hydrobromide is available at your pharmacy, since these approved generics should cost significantly less than the brand. You can also apply for the manufacturer’s savings card through the Aplenzin website if you have commercial insurance. Just be aware of the annual cap on benefits and plan accordingly if your copay starts climbing mid-year.
Pharmacy discount programs like GoodRx or RxSaver sometimes negotiate lower cash prices for brand medications, though with a list price this high, the discount may still leave you with a substantial bill. Comparing prices across pharmacies, including mail-order options, can sometimes reveal meaningful differences.